Overview

Novel therapies for soft tissue and bone sarcomas

Positions

Professor of Medicine in the School of Medicine

2024 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

2000 School of Medicine

Education

M.D. 2000

2000 Thomas Jefferson University

Resident in Medicine, Medicine

2003 Duke University

Fellow in Hematology-Oncology, Medicine

2004 Duke University

Fellow in Hematology-Oncology, Medicine

2007 Duke University

Clinical Trials

EA7211 STRASS 2 High Risk Retroperitoneal Sarcoma

Servier "CHONQUER" (IDH1-mutated locally advanced or metastatic chondrosarcoma)

ECOG EA7222 Doxo + pembro vs Doxorubicin for undifferentiated pleomorphic and related sarcomas

Tangent- emactuzumab vs placebo in Tenosynovial Giant Cell Tumor

Invincible-3 Trial (Recurrent, Metastatic Soft Tissue Sarcoma)

Load More

Publications, Grants & Awards

• Grants (40)
• Academics Articles (109)
• Conference Pages (49)
• Book Sections (3)

Showing 1-5 of 40

A Phase II, Multi-centre, Randomised, Double-blind, Group Comparator Trial to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Patients with Tenosynovial Giant Cell Tumour,

2025-2030SynOx Therapeutics Ltd

A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adult Participants With Locally Recurrent, InoperaBLE,orMetastatic

2024-2029Intensity Therapeutics, Inc.

A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ?18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1

2024-2029Servier Bio-Innovation, LLC

Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies

2023-2029Adaptimmune LLC

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

2023-2029Adaptimmune LLC

DCI Centers, Cancer Types & Labs

Duke Sarcoma Center

Offices & Contact

Dept of Medicine
Durham, NC
27710

Duke Box 3198
Durham, NC
27710